Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIISC-THETIS: Colchicine and Ticagrelor in Ischemic Stroke
NCT05476991Phase 3Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- May 2023
- Primary completion
- Sep 2027
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of colchicine, ticagrelor in ischemic stroke, Transient Ischemic Attack (TIA), sponsored by Assistance publique - Hôpitaux de Paris. Started May 2023; status: recruiting.
02
Drugs
colchicineticagrelor
03
Conditions
ischemic strokeTransient Ischemic Attack (TIA)
Beyond the preview
Go deeper on NCT05476991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05476991.